{
  "pmcid": "12499376",
  "sha256": "3ad17130c8dc83b8ebfc85f0432202e0742ef7a96b0ea9a49ac1c5eb23ed468a",
  "timestamp_utc": "2025-11-09T23:42:08.863570+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.380434782608695,
    "reading_ease": 32.37777591973247,
    "word_count": 276
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Long-term Outcomes of Invasive vs. Noninvasive Treatments for Intermittent Claudication: A Systematic Review and Meta-Analysis of Randomised Controlled Trials"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults diagnosed with IC."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Interventions included invasive treatments (angioplasty, revascularization) and noninvasive treatments (supervised exercise therapy, best medical therapy)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the long-term outcomes of invasive versus noninvasive treatments for IC."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcomes were quality of life (QoL), ankle-brachial pressure index (ABPI), and maximum walking distance (MWD) over 2 to 7 years."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not specified."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding details were not provided."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 1379 patients from 11 RCTs were included."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Invasive treatments significantly improved MWD (pooled MD = 64.94, 95% CI [10.77, 115.12], p = .02) and ABPI (pooled MD = 0.15, 95% CI [0.04, 0.26], p = .006)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent in the invasive group, though not statistically significant."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: PROSPERO CRD42023494962."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}